Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson’s Disease

2017 ◽  
Vol 7 (2) ◽  
pp. 279-287 ◽  
Author(s):  
Patrick T. Hickey ◽  
Maragatha Kuchibhatla ◽  
Burton Scott ◽  
Lisa Gauger ◽  
Mark A. Stacy
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Transporter ◽  
Functional Outcomes ◽  
De Novo ◽  
Dopamine Transporter Imaging

scholarly journals Refining diagnosis of Parkinson's disease with deep learning-based interpretation of dopamine transporter imaging

2017 ◽  
Vol 16 ◽  
pp. 586-594 ◽  
Author(s):  
Hongyoon Choi ◽  
Seunggyun Ha ◽  
Hyung Jun Im ◽  
Sun Ha Paek ◽  
Dong Soo Lee
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Learning ◽  
Dopamine Transporter ◽  
Dopamine Transporter Imaging

scholarly journals Clinical diagnosis of Lewy body dementia

BJPsych Open ◽  
2020 ◽  
Vol 6 (4) ◽  
Author(s):  
Ajenthan Surendranathan ◽  
Joseph P. M. Kane ◽  
Allison Bentley ◽  
Sally A. H. Barker ◽  
John-Paul Taylor ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Dopamine Transporter ◽  
Lewy Body ◽  
Lewy Bodies ◽  
Lewy Body Dementia ◽  
Final Diagnosis ◽  
Dopamine Transporter Imaging ◽  
The Uk

Background Lewy body dementia, consisting of both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is considerably under-recognised clinically compared with its frequency in autopsy series. Aims This study investigated the clinical diagnostic pathways of patients with Lewy body dementia to assess if difficulties in diagnosis may be contributing to these differences. Method We reviewed the medical notes of 74 people with DLB and 72 with non-DLB dementia matched for age, gender and cognitive performance, together with 38 people with PDD and 35 with Parkinson's disease, matched for age and gender, from two geographically distinct UK regions. Results The cases of individuals with DLB took longer to reach a final diagnosis (1.2 v. 0.6 years, P = 0.017), underwent more scans (1.7 v. 1.2, P = 0.002) and had more alternative prior diagnoses (0.8 v. 0.4, P = 0.002), than the cases of those with non-DLB dementia. Individuals diagnosed in one region of the UK had significantly more core features (2.1 v. 1.5, P = 0.007) than those in the other region, and were less likely to have dopamine transporter imaging (P < 0.001). For patients with PDD, more than 1.4 years prior to receiving a dementia diagnosis: 46% (12 of 26) had documented impaired activities of daily living because of cognitive impairment, 57% (16 of 28) had cognitive impairment in multiple domains, with 38% (6 of 16) having both, and 39% (9 of 23) already receiving anti-dementia drugs. Conclusions Our results show the pathway to diagnosis of DLB is longer and more complex than for non-DLB dementia. There were also marked differences between regions in the thresholds clinicians adopt for diagnosing DLB and also in the use of dopamine transporter imaging. For PDD, a diagnosis of dementia was delayed well beyond symptom onset and even treatment.

Sign in / Sign up

Export Citation Format

Share Document